Organon & Co. (OGN) Competitors $10.07 -0.08 (-0.74%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$10.06 -0.02 (-0.20%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. MRNA, BPMC, BBIO, VRNA, ROIV, RVMD, ELAN, LEGN, TGTX, and GRFSShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Its Competitors Moderna Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech TG Therapeutics Grifols Moderna (NASDAQ:MRNA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Does the media refer more to MRNA or OGN? In the previous week, Organon & Co. had 32 more articles in the media than Moderna. MarketBeat recorded 51 mentions for Organon & Co. and 19 mentions for Moderna. Moderna's average media sentiment score of 0.22 beat Organon & Co.'s score of 0.05 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Organon & Co. 3 Very Positive mention(s) 3 Positive mention(s) 39 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts recommend MRNA or OGN? Moderna currently has a consensus target price of $46.61, indicating a potential upside of 52.97%. Organon & Co. has a consensus target price of $18.00, indicating a potential upside of 78.66%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is MRNA or OGN more profitable? Organon & Co. has a net margin of 11.92% compared to Moderna's net margin of -105.67%. Organon & Co.'s return on equity of 227.43% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% Organon & Co. 11.92%227.43%7.34% Which has higher valuation & earnings, MRNA or OGN? Organon & Co. has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.64-$3.56B-$8.73-3.49Organon & Co.$6.40B0.41$864M$2.883.50 Do institutionals & insiders believe in MRNA or OGN? 75.3% of Moderna shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, MRNA or OGN? Moderna has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. SummaryOrganon & Co. beats Moderna on 11 of the 16 factors compared between the two stocks. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Medical Services IndustryMedical SectorNYSE ExchangeMarket Cap$2.64B$7.29B$5.54B$20.55BDividend Yield0.79%2.78%5.38%3.75%P/E Ratio3.5027.9427.4028.05Price / Sales0.4132.39419.6545.87Price / Cash2.0622.0836.6322.31Price / Book5.516.698.084.59Net Income$864M$233.06M$3.16B$985.44M7 Day Performance2.09%1.74%2.84%2.78%1 Month Performance5.61%3.97%3.70%5.40%1 Year Performance-50.39%35.84%35.31%14.61% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.8289 of 5 stars$10.08-0.7%$18.00+78.7%-50.4%$2.64B$6.40B3.504,000Trending NewsMRNAModerna4.3855 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$9.93B$3.14B-2.945,800Options VolumeBPMCBlueprint Medicines1.7305 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.29B$508.82M-51.98640BBIOBridgeBio Pharma4.7066 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$8.01B$127.42M-11.95400News CoverageAnalyst ForecastInsider TradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6467 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$7.87B$118.54M-48.5330Positive NewsAnalyst ForecastROIVRoivant Sciences1.9503 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.82B$29.05M-46.00860RVMDRevolution Medicines4.5693 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.46B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.2493 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.64B$4.43B18.059,000Analyst ForecastLEGNLegend Biotech3.2538 of 5 stars$33.85-0.4%$76.20+125.1%-23.0%$6.22B$627.24M-57.372,609Analyst ForecastTGTXTG Therapeutics3.1627 of 5 stars$36.56+1.5%$40.80+11.6%+98.0%$5.80B$329M152.33290GRFSGrifols4.0501 of 5 stars$8.37-4.6%$10.30+23.1%+36.7%$5.75B$7.81B7.1523,822 Related Companies and Tools Related Companies MRNA Alternatives BPMC Alternatives BBIO Alternatives VRNA Alternatives ROIV Alternatives RVMD Alternatives ELAN Alternatives LEGN Alternatives TGTX Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
